Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 16,142 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Cancer
Interventions: DermaMatrix, standard of care tissue expander breast reconstruction surgery after mastectomy; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more

Conditions: Atopic Dermatitis
Interventions: BRT-FC-83C; Device
Lead sponsor: Biomed Research & Technologies, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions: CARE, TARE, Home-Based Stretching; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 20 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions: Selumetinib, MEDI4736, Tremelimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more

Conditions: Breast Cancer, Radiation-Induced Telangiectasias
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Alloderm, Questionnaires, Without ALLODERM, Questionnaires; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 3
States / cities: Ann Arbor, Michigan • New York, New York • Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: GDC-4198, Giredestrant, Abemaciclib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Huntsville, Alabama • Tucson, Arizona • Duarte, California + 29 more

Conditions: Melanoma, Skin Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 4,082 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Melanoma
Interventions: HSPPC-96 or Oncophage; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more

Conditions: Melanoma
Interventions: ILX651; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Breast Cancer
Interventions: Bilateral mastectomy with reconstruction; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Interventions: BNT111, Cemiplimab; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more

Conditions: Breast Cancer
Interventions: D-0502, palbociclib; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Breast Reconstruction With Silicone Implants
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions: Total Knee Arthroplasty; Procedure
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 12
States / cities: Atlanta, Georgia • Boston, Massachusetts • Novi, Michigan + 8 more

Conditions: Nail Psoriasis, Nail Diseases
Interventions: Placebos, Triamcinolone Acetonide 2.5 mg/mL, Triamcinolone Acetonide 5.0 mg/mL, Triamcinolone Acetonide 7.5 mg/mL, Triamcinolone Acetonide 10 mg/mL; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Physical activity counseling; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Skin Disorder
Interventions: Diffuse Reflectance Spectroscopy, BiliChek; Device · Diagnostic Test
Lead sponsor: University of Arkansas; Other
Eligibility: 24 Hours to 6 Months
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Eczema, Atopic Dermatitis
Interventions: Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy; Drug · Device
Lead sponsor: OptiSkin Medical; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells; Biological
Lead sponsor: The Foundation for Orthopaedics and Regenerative Medicine; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions: Exemestane, Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions: MT-4561; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more

Search by objective public record fields.

Use of Dermal Matrix in Breast Reconstruction

T and B Cell Responses in Autoimmune Diseases

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

Taking AIM at Breast Cancer

The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser

Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

A Model for Genetic Susceptibility: Melanoma

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

McGhan Medical Silicone-Filled Breast Implant Adjunct Study

A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

Physical Activity Promotion in Cancer Follow-Up Care

Characterization of Pre-Term Neonatal Skin

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

A Study of MT-4561 in Patients With Various Advanced Solid Tumors